Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 14/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (4-Chlorophenyl)(Cyclopropyl)Methanone SCHEMBL6220062 | 0.96 | MGLL (0.64) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL894800 | 0.92 | MGLL (0.60) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL894802 | 0.92 | MGLL (0.60) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL2322628 | 0.91 | MGLL (0.64) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL14470562 | 0.90 | MGLL (0.58) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL19472848 | 0.90 | MGLL (0.58) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL196518 | 0.90 | SRD5A2 (0.62) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL2297101 | 0.86 | MGLL (0.58) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL654532 | 0.86 | MEN1 (0.67) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL13657578 | 0.85 | MGLL (0.71) | MGLLMEN1KMT2ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115584014-A | Ladder-shaped polymer material with heat-resisting and fluorescent characteristics and preparation method thereof | 大连理工大学 | 2023-01-10 | — | — | CN | claimed |
| CN-106986887-A | A kind of method for preparing 4 ring the third methylene-benzene boric acid | 蚌埠中实化学技术有限公司 | 2017-07-28 | — | — | CN | claimed |
| US-12252495-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2025-03-18 | — | — | US | disclosed |
| CN-115784857-B | 4-Fluorophenyl cyclopropyl ketone-14C and preparation method thereof | 长沙贝塔医药科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-04 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| CN-115784857-A | 4-fluorophenyl cyclopropyl ketone- 14 C and preparation method thereof | 长沙贝塔医药科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115584014-A | Ladder-shaped polymer material with heat-resisting and fluorescent characteristics and preparation method thereof | 大连理工大学 | 2023-01-10 | — | — | CN | disclosed |
| US-20220234996-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-11377417-B2 | Branched 3-phenylpropionic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-07-05 | — | — | US | disclosed |
| US-4975451-A | Insecticidal cyclopropyl di(aryl) 2-butenes | FMC CORPORATION (US) | 1990-12-04 | — | — | US | disclosed |
| EP-0357610-A1 | INSECTICIDAL CYCLOPROPYL-SUBSTITUTED DI(ARYL) COMPOUNDS. | FMC CORP (US) | 1990-03-14 | — | — | EP | disclosed |
| US-4808762-A | Insecticidal cyclopropyl-substituted di(aryl) compounds | FMC CORPORATION (US) | 1989-02-28 | — | — | US | disclosed |
| WO-1988008416-A1 | INSECTICIDAL CYCLOPROPYL-SUBSTITUTED DI(ARYL) COMPOUNDS | FMC CORPORATION (US) | 1988-11-03 | — | — | WO | disclosed |
| US-4596872-A | Imidazo[1,2-a]pyridines, and process for their preparation | SCHERING A.G. (DE) | 1986-06-24 | — | — | US | disclosed |
| US-4434182-A | Insecticidal substituted-biphenylmethyl oxime ethers | FMC CORPORATION (US) | 1984-02-28 | — | — | US | disclosed |
| US-RE30634-E | INSECTICIDES | SHELL OIL COMPANY (US) | 1981-06-02 | — | — | US | disclosed |
| US-4137324-A | Optionally substituted phenyl-α-cyclopropyl acetic acid esters and use as insecticides | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4079149-A | INSECTICIDES | SHELL OIL COMPANY (US) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | MGLL 4423/4885MEN1 613/4885KMT2A 1343/4885 |
| US-20220234996-A1 | Method for Producing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic Acid and the Crystalline Form Thereof for Use as a Pharmaceutical Ingredient | FABP3, PCCA, HMGCR | MGLL 1591/4885MEN1 4702/4885KMT2A 4532/4885 |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | MGLL 4423/4885MEN1 613/4885KMT2A 1343/4885 |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | MGLL 4423/4885MEN1 613/4885KMT2A 1343/4885 |
| US-11377417-B2 | Branched 3-phenylpropionic acid derivatives and their use | PC, FABP3, PCCA | MGLL 909/4885MEN1 3760/4885KMT2A 4313/4885 |
| US-11760760-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | MGLL 4423/4885MEN1 613/4885KMT2A 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.